Rxsight, Inc. (RXST)
NASDAQ:RXST
Want to see RXST full AI Analyst Report?
Earnings Data
Report Date
Aug 10, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.36Last Year’s EPS
-0.29Same Quarter Last Year
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a mixed picture: operational positives include stabilized LAL procedure volumes, improved gross margin in Q1, a major commercial milestone (300,000 implants), early signs of success from customer reengagement programs, and maintained full-year revenue guidance. Offsetting these are sizable near-term challenges — an 18% YoY revenue decline, weak LDD capital placements (only 20 sold), a Q1 net loss of $15.9M, increased SG&A/OpEx investments, and anticipated margin pressure from higher-cost inventory that will weigh on near-term profitability. Management projects gradual sequential improvement and is investing to drive longer-term growth, but near-term financial headwinds and modest 2026 volume expectations temper the outlook.Company Guidance
Stabilized LAL Volumes and Customer Reengagement Progress
LAL unit volumes of 27,472 in Q1 were in line with the year-ago period and represent stabilization for the third consecutive quarter; management reported early, localized success from customer reengagement programs (clinical outcome reviews, counseling training, workflow support) and expects sequential improvement through the year.
Revenue Mix and Gross Margin Expansion
Higher mix of LAL revenue led to a gross margin of 76.1% in Q1 versus 74.8% a year ago (approx +1.3 percentage points), reflecting stronger LAL contribution (LAL sales approx $27M, ~88% of total sales).
Key Commercial Milestone — 300,000 LAL Implants
Company announced an important adoption milestone of 300,000 Light Adjustable Lens (LAL) implants since U.S. commercialization, supporting clinical traction and market penetration.
Conservative but Maintained Full-Year Guidance
RxSight reiterated full-year 2026 revenue guidance of $120 million to $135 million and gross margin guidance of 70% to 72%, indicating management confidence in achieving previously communicated targets despite near-term headwinds.
International Expansion Progress
Received regulatory approval in New Zealand and noted early commercial introductions and growing awareness in markets such as Korea, Singapore, Europe, Australia and New Zealand; management expects international to be a modest contributor in 2026 with more meaningful impact in 2027+.
Strong Clinician Preference Signal
Survey data cited on the call showed nearly 80% of ophthalmologists and optometrists would choose the LAL for themselves or a loved one, reinforcing perceived clinical differentiation and potential demand.
RXST Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RXST Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | $6.78 | $5.80 | -14.45% |
Feb 25, 2026 | $8.81 | $7.92 | -10.10% |
Nov 05, 2025 | $8.34 | $8.61 | +3.24% |
Aug 07, 2025 | $7.79 | $7.19 | -7.70% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Rxsight, Inc. (RXST) report earnings?
Rxsight, Inc. (RXST) is schdueled to report earning on Aug 10, 2026, After Close (Confirmed).
What is Rxsight, Inc. (RXST) earnings time?
Rxsight, Inc. (RXST) earnings time is at Aug 10, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RXST EPS forecast?
RXST EPS forecast for the fiscal quarter 2026 (Q2) is -0.36.